Objective: Improve the care of patients followed for acute leukemia in the Oncohematology department of the National Hospital of Niamey. Methods: This was a prospective study, over a period of 2 years from January 1, 2018 to December 31, 2019, in patients with acute leukemia in the Oncohematology department of the National Hospital of Niamey (HNN), whose diagnosis was made on a blood smear associated with a myelogram and immunophenotyping and who were consenting. Results: We collected 25 cases of acute leukemia confirmed by myelogram and immunophenotyping. The mean age of the patients was 31.32 years, with a predominance of women, a sex ratio of 0.92. Pupils and students were in the majority with 40% and most came from the Niamey region, i.e. 68%. Anemic syndrome was the most common clinical sign in 96%. ALL predominated in 64% of cases. On the blood count, the hyperleukocytosis was more marked in AML (mean white count: 197256.6 elts/mm3) than in ALL (137891.6 elts/mm3), it was the same for thrombocytopenia which is more marked in AML (75588.89/mm3) than in ALL (52156.25/mm3). Therapeutically, 52% of patients received chemotherapy. The mean overall survival was 16.223 ± 3.191 months, including a mean survival for AML of 6.853 ± 1200 months compared to 21.720 ± 5.920 months for ALL. Conclusion: Acute leukemia still remains a major problem in our context, due to the precariousness of limited financial, diagnostic and therapeutic resources. Thus reflecting in our results, the increasing number of cases, the diagnostic delay and the guarded prognosis. This is the reality in several other countries in the sub-region and even in certain developed countries.
References
[1]
Sandler, D.P. and Ross, J.A. (1997) Epidemiology of Acute Leukemia in Children and Adults. Seminars in Oncology, 24, 3-16.
[2]
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
[3]
Lotodo, T., et al. (2022) Geographical Distribution of Hematological Malignancies Managed at Moi Teaching and Referral Hospital. East African Medical Journal, 99, Article No. 3. https://www.ajol.info/index.php/eamj/article/view/226457
[4]
Ngamai, B. (2010) Epidemiological, Diagnostic, and Therapeutic Aspects of Acute Leukemias in Children in the Three University Hospitals (CHU) of Burkina Faso. Thesis of Medecine. https://www.bibliosante.ml/handle/123456789/9185
[5]
Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., et al. (2016) The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia. Blood, 127, 2391-2405. https://doi.org/10.1182/blood-2016-03-643544
[6]
Ngolet, L.O., Luokdom, S.J., Liboko, A.F.B., Tsiba, F.O.G.A. and Dokekias, A.E. (2022) Evolution of the Outcomes of Children with Acute Leukemia in Congo. Open Journal of Blood Diseases, 12, 1-9. https://doi.org/10.4236/ojbd.2022.121001
[7]
Ouedraogo, R.C. (2008) Acute Leukemias in Children in Pediatric Hospital Settings in Ouagadougou: A Retro-Prospective Study over Ten Years. Thesis of Medecine. https://pubmed.ncbi.nlm.nih.gov/29875926
[8]
Mbensa, L., Ngiyulu, R., Binda, P., et al. (1993) Acute Leukemia in Children: Index and Clinical Manifestations in Tropical Environments. Medecined’Afrique Noire, 40, 555-556.
[9]
Estey, E. and Döhner, H. (2006) Acute Myeloid Leukaemia. TheLancet, 368, 1894-1907. https://doi.org/10.1016/s0140-6736(06)69780-8
[10]
Sojitra, P., Arber, D.A. and George, T.I. (2017) ASH-CAP Guidelines for the Diagnosis of Acute Leukemia. TheHematologist, 14, 11-16. https://doi.org/10.1182/hem.v14.2.7120
[11]
Lotodo, T., Patel, K. and Ndede, I. (2023) Laboratory Diagnosis of Acute Leukemia in Kenya: The Gaps and Opportunities. JournalofBiosciencesandMedicines, 11, 93-105. https://doi.org/10.4236/jbm.2023.1112009
[12]
Mounkaila, B., Touré, I.A., Gragnic, G., et al. (1996) Malignant Hematological Disorders in Niamey: About 90 Observations over 6 Years. Medecined’Afrique Noire, 43, 8-9.
[13]
Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., et al. (2009) The 2008 Revision of the World Health Organization (WHO) Classification of Myeloid Neoplasms and Acute Leukemia: Rationale and Important Changes. Blood, 114, 937-951. https://doi.org/10.1182/blood-2009-03-209262
[14]
Valensi, F. (2003) Classification of Acute Leukemias. Contribution of the World Health Organization’s Proposals. EMC (Elsevier Masson SAS, Paris).
[15]
Orkin, S.H. and Zon, L.I. (2008) Hematopoiesis: An Evolving Paradigm for Stem Cell Biology. Cell, 132, 631-644. https://doi.org/10.1016/j.cell.2008.01.025
[16]
Döhner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Büchner, T., Burnett, A.K., et al. (2010) Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations from an International Expert Panel, on Behalf of the European Leukemianet. Blood, 115, 453-474. https://doi.org/10.1182/blood-2009-07-235358
[17]
Inaba, H., Greaves, M. and Mullighan, C.G. (2013) Acute Lymphoblastic Leukaemia. TheLancet, 381, 1943-1955. https://doi.org/10.1016/s0140-6736(12)62187-4
[18]
Gardin, C., Turlure, P., Fagot, T., Thomas, X., Terre, C., Contentin, N., et al. (2007) Postremission Treatment of Elderly Patients with Acute Myeloid Leukemia in First Complete Remission after Intensive Induction Chemotherapy:results of the Multicenter Randomized Acute Leukemia French Association (ALFA) 9803 Trial. Blood, 109, 5129-5135. https://doi.org/10.1182/blood-2007-02-069666
[19]
Byrd, J.C., Ruppert, A.S., Mrózek, K., Carroll, A.J., Edwards, C.G., Arthur, D.C., et al. (2004) Repetitive Cycles of High-Dose Cytarabine Benefit Patients with Acute Myeloid Leukemia and Inv(16) (p13q22) or T(16; 16) (p13; q22): Results from CALGB 8461. JournalofClinicalOncology, 22, 1087-1094. https://doi.org/10.1200/jco.2004.07.012
[20]
Bloomfield, C.D., Lawrence, D., Byrd, J.C., et al. (1998) Frequency of Prolonged Remission Duration after High-Dose Cytarabine Intensification in Acute Myeloid Leukemia Varies by Cytogenetic Subtype. Cancer Research, 58, 4173-4179.
[21]
Thomas, X., Suciu, S., Rio, B., Leone, G., Broccia, G., Fillet, G., et al. (2007) Autologous Stem Cell Transplantation After Complete Remission and First Consolidation in Acute Myeloid Leukemia Patients Aged 61 70 Years: Results of the Prospective EORTC GIMEMA AML 13 Study. Haematologica, 92, 389-396. https://doi.org/10.3324/haematol.10552
[22]
Dombret, H., Cluzeau, T., Huguet, F. and Boissel, N. (2014) Pediatric-Like Therapy for Adults with All. CurrentHematologicMalignancyReports, 9, 158-164. https://doi.org/10.1007/s11899-014-0210-9
[23]
Lamanna, N., Heffner, L.T., Kalaycio, M., Schiller, G., Coutre, S., Moore, J., et al. (2012) Treatment of Adults with Acute Lymphoblastic Leukemia: Do the Specifics of the Regimen Matter? Results from a Prospective Randomized Trial. Cancer, 119, 1186-1194. https://doi.org/10.1002/cncr.27901
[24]
Hunault-Berger, M., Leguay, T., Thomas, X., Legrand, O., Huguet, F., Bonmati, C., et al. (2010) A Randomized Study of Pegylated Liposomal Doxorubicin versus Continuous-Infusion Doxorubicin in Elderly Patients with Acute Lymphoblastic Leukemia: The GRAALL-SA1 Study. Haematologica, 96, 245-252. https://doi.org/10.3324/haematol.2010.027862
[25]
Thomas, D.A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., et al. (2010) Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. JournalofClinicalOncology, 28, 3880-3889. https://doi.org/10.1200/jco.2009.26.9456
